Article | October 18, 2024

Johnson & Johnson To Invest $2B On New Biologics Facility In Wilson, Create 420 Jobs

Monoclonal antibody MAB GettyImages-1294461540

Johnson & Johnson, a New Jersey-based global healthcare and medical technology firm, is set to invest over $2 billion in a new biologics manufacturing facility in Wilson, North Carolina. The facility will focus on the production of monoclonal antibodies and will cover more than 300,000 square feet in the Wilson Corporate Park, generating 420 jobs over the next five years. Continue reading to learn more about this promising life sciences investment.

access the Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

North Carolina Biotechnology Center